IL274518B2 - שימוש בטיפול בקרינה ממוקד להניע תגובה חיסונית נגד גידול לטיפולים חיסוניים - Google Patents

שימוש בטיפול בקרינה ממוקד להניע תגובה חיסונית נגד גידול לטיפולים חיסוניים

Info

Publication number
IL274518B2
IL274518B2 IL274518A IL27451820A IL274518B2 IL 274518 B2 IL274518 B2 IL 274518B2 IL 274518 A IL274518 A IL 274518A IL 27451820 A IL27451820 A IL 27451820A IL 274518 B2 IL274518 B2 IL 274518B2
Authority
IL
Israel
Prior art keywords
tumor
antibody
trt
opochchnmeo
cancer
Prior art date
Application number
IL274518A
Other languages
English (en)
Other versions
IL274518B1 (he
IL274518A (he
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/809,427 external-priority patent/US11633506B2/en
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of IL274518A publication Critical patent/IL274518A/he
Publication of IL274518B1 publication Critical patent/IL274518B1/he
Publication of IL274518B2 publication Critical patent/IL274518B2/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0408—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A61N2005/1019—Sources therefor
    • A61N2005/1021—Radioactive fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL274518A 2017-11-10 2018-11-09 שימוש בטיפול בקרינה ממוקד להניע תגובה חיסונית נגד גידול לטיפולים חיסוניים IL274518B2 (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/809,427 US11633506B2 (en) 2016-07-18 2017-11-10 Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
PCT/US2018/059927 WO2019094657A1 (en) 2017-11-10 2018-11-09 Using targeted radiotherapy (trt) to drive anti-tumor immune response to immunotherapies

Publications (3)

Publication Number Publication Date
IL274518A IL274518A (he) 2020-06-30
IL274518B1 IL274518B1 (he) 2026-02-01
IL274518B2 true IL274518B2 (he) 2026-06-01

Family

ID=64665595

Family Applications (2)

Application Number Title Priority Date Filing Date
IL274518A IL274518B2 (he) 2017-11-10 2018-11-09 שימוש בטיפול בקרינה ממוקד להניע תגובה חיסונית נגד גידול לטיפולים חיסוניים
IL325659A IL325659A (he) 2017-11-10 2025-12-28 שימוש בטיפול בקרינה ממוקד להניע תגובה חיסונית נגד גידול לטיפולים חיסוניים

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL325659A IL325659A (he) 2017-11-10 2025-12-28 שימוש בטיפול בקרינה ממוקד להניע תגובה חיסונית נגד גידול לטיפולים חיסוניים

Country Status (8)

Country Link
EP (1) EP3706808A1 (he)
JP (3) JP2021502368A (he)
KR (1) KR102758660B1 (he)
CN (2) CN111565762A (he)
AU (2) AU2018366219B2 (he)
CA (1) CA3082056A1 (he)
IL (2) IL274518B2 (he)
WO (1) WO2019094657A1 (he)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220008570A1 (en) * 2018-12-21 2022-01-13 Actinium Pharmaceuticals, Inc. Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
IL324962A (he) 2019-11-27 2026-01-01 Gi Innovation Inc תכשיר רוקחות לטיפול בסרטן המכיל חלבון איחוי המכיל חלבון 2-il וחלבון 80cd ומעכב נקודת ביקורת חיסונית
EP3842097A1 (en) * 2019-12-23 2021-06-30 Koninklijke Philips N.V. Planning radiation therapy using a personalized hematologic risk score
WO2021154746A1 (en) 2020-01-28 2021-08-05 Reflexion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy
AU2021244617A1 (en) 2020-03-26 2022-11-10 Migdalia FORT Ultraviolet radiation treatments
CN111840585B (zh) * 2020-07-20 2022-05-03 厦门大学 一种用于肿瘤免疫治疗的药物组合
US11964168B2 (en) 2021-06-10 2024-04-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for prostate cancer
US20220395702A1 (en) * 2021-06-10 2022-12-15 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
CN118382465A (zh) * 2021-12-14 2024-07-23 波士顿科学国际有限公司 放射性的剪切稀化生物材料组合物及其使用方法
JP2025503213A (ja) * 2022-01-28 2025-01-30 フュージョン ファーマシューティカルズ インコーポレイテッド Ｎｔｓｒ１標的化放射性医薬品およびチェックポイント阻害剤併用療法
WO2024258913A1 (en) * 2023-06-16 2024-12-19 Wisconsin Alumni Research Foundation Treatment of solid tumors with a regimen of targeted radionuclide therapy and genetically engineered immune cell therapies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017207732A1 (en) * 2016-06-02 2017-12-07 Welltec A/S Downhole power supply device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
DE602005015687D1 (de) * 2004-03-02 2009-09-10 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
MX2007007497A (es) * 2004-12-20 2008-01-11 Cellectar Llc Analogos de fosfolipido eter para la deteccion y tratamiento del cancer.
DK3708192T3 (da) * 2009-06-12 2023-11-06 Cellectar Inc Etherphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
HK1254404A1 (zh) * 2015-06-25 2019-07-19 Advanced Accelerator Applications 治疗过度表达生长抑素受体的神经内分泌肿瘤的方法
US20180214583A1 (en) * 2015-08-12 2018-08-02 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
WO2017079535A1 (en) * 2015-11-06 2017-05-11 Wisconsin Alumni Research Foundation Long-lived gadolinium based tumor targeted imaging and therapy agents
KR102396334B1 (ko) * 2016-07-18 2022-05-09 위스콘신 얼럼나이 리서어치 화운데이션 인 시츄 면역 조절 암 백신화를 위한 방사성할로겐화 제제
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
US20180022768A1 (en) 2016-07-25 2018-01-25 Wisconsin Alumni Research Foundation Radioactive phospholipid metal chelates for cancer imaging and therapy
KR102396324B1 (ko) * 2016-07-25 2022-05-09 위스콘신 얼럼나이 리서어치 화운데이션 인 시츄 면역 조절 암 백신화를 위한 표적화된 방사선요법 킬레이트

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017207732A1 (en) * 2016-06-02 2017-12-07 Welltec A/S Downhole power supply device

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FONG, L ET AL., A PHASE IB TRIAL TO STUDY THE SAFETY AND TOLERABILITY OF ATEZOLIZUMAB WITH RADIUM-223 DICHLORIDE IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC)., 1 July 2017 (2017-07-01) *
STORKUS W., COMBINATION TREATMENT OF VLA-4 TARGETED RADIONUCLIDE THERAPY IMMUNOTHERAPY FOR METASTATIC MELANOMA., 16 September 2017 (2017-09-16) *
SWART, M. ET AL., COMBINATION APPROACHES WITH IMMUNE-CHECKPOINT BLOCKADE IN CANCER THERAPY., 1 November 2016 (2016-11-01) *

Also Published As

Publication number Publication date
JP7839135B2 (ja) 2026-04-01
CN111565762A (zh) 2020-08-21
IL274518B1 (he) 2026-02-01
WO2019094657A1 (en) 2019-05-16
JP2021502368A (ja) 2021-01-28
CN120550150A (zh) 2025-08-29
AU2018366219A1 (en) 2020-06-11
KR102758660B1 (ko) 2025-01-22
EP3706808A1 (en) 2020-09-16
JP2026102802A (ja) 2026-06-23
CA3082056A1 (en) 2019-05-16
JP2023179556A (ja) 2023-12-19
KR20200088374A (ko) 2020-07-22
IL274518A (he) 2020-06-30
AU2018366219B2 (en) 2025-09-11
AU2025271049A1 (en) 2025-12-11
IL325659A (he) 2026-02-01